KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amneal Pharmaceuticals (AMRX) Debt to Equity (2017 - 2026)

Amneal Pharmaceuticals has reported Debt to Equity over the past 9 years, most recently at -$35.96 for Q4 2025.

  • For Q4 2025, Debt to Equity fell 74.12% year-over-year to -$35.96; the TTM value through Dec 2025 reached -$35.96, down 74.12%, while the annual FY2025 figure was -$35.96, 74.12% down from the prior year.
  • Debt to Equity for Q4 2025 was -$35.96 at Amneal Pharmaceuticals, down from -$23.51 in the prior quarter.
  • Over five years, Debt to Equity peaked at $120.94 in Q4 2023 and troughed at -$41.79 in Q2 2024.
  • A 5-year average of $1.02 and a median of $6.84 in 2021 define the central range for Debt to Equity.
  • Biggest five-year swings in Debt to Equity: skyrocketed 3900.81% in 2021 and later plummeted 336.08% in 2024.
  • Year by year, Debt to Equity stood at $7.39 in 2021, then skyrocketed by 92.94% to $14.25 in 2022, then skyrocketed by 748.62% to $120.94 in 2023, then tumbled by 117.08% to -$20.65 in 2024, then tumbled by 74.12% to -$35.96 in 2025.
  • Business Quant data shows Debt to Equity for AMRX at -$35.96 in Q4 2025, -$23.51 in Q3 2025, and -$19.35 in Q2 2025.